All In Biotech

Drug Trial Radar · NCT04567303

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

A Three-part, Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

177

Actual

Start

Oct 28, 2020

Primary completion

Aug 25, 2026

Study completion Aug 25, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).

Conditions

  • Macular Degeneration

Interventions

  • ZifibancimigDrug

    Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter (µL) in the study eye. Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant. Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.

  • RanibizumabDrug

    Participants will receive ranibizumab 100 mg/mL through the PD implant

  • Port Delivery PlatformDevice

    Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs)Time frame: Part 1: Baseline up to Week 24; Parts 2 & 3: Baseline up to Week 48
  2. Percentage of Participants With Ocular AEs During the Post-operative and Follow-up PeriodsTime frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)
  3. Percentage of Participants With Adverse Events of Special Interest (AESIs) Including Ocular AESIsTime frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 48
  4. Percentage of Participants With Ocular AESIs During the Post-operative and Follow-up PeriodsTime frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)
  5. Duration of Ocular AESIsTime frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 48
  6. Duration of Ocular AESIs During the Post-operative and Follow-up PeriodsTime frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)
  7. Percentage of Participants With Adverse Device Effects (ADEs)Time frame: Parts 2 and 3: Baseline up to Week 48
  8. Duration of ADEsTime frame: Parts 2 and 3: Baseline up to Week 48
  9. Percentage of Participants With Anticipated Serious ADEs (ASADEs)Time frame: Parts 2 and 3: Baseline up to Week 48
  10. Duration of ASADEsTime frame: Parts 2 and 3: Baseline up to Week 48
  11. Change From Baseline in Early Treatment Diabetic Retinopathy Study - Best Corrected Visual Acuity (ETDRS-BCVA) Score at Week 48Time frame: Part 3: Baseline (baseline visit, before implant insertion), and Week 48

Locations

37 sites in 2 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center

    Mesa, Arizona

  • Associated Retina Consultants

    Phoenix, Arizona

  • The Retina Partners

    Encino, California

  • Retinal Consultants Med Group

    Sacramento, California

  • Orange County Retina Med Group

    Santa Ana, California

  • Southwest Retina Consultants

    Durango, Colorado

  • Retina Vitreous Assoc of FL

    St. Petersburg, Florida

  • Southern Vitreoretinal Assoc

    Tallahassee, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Maine Eye Center

    Portland, Maine

  • Johns Hopkins Med

    Baltimore, Maryland

  • Retina Group of Washington

    Chevy Chase, Maryland

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Foundation for Vision Research

    Grand Rapids, Michigan

  • Associated Retinal Consultants

    Royal Oak, Michigan

  • VitreoRetinal Surgery, PLLC.

    Saint Louis Park, Minnesota

  • The Retina Institute

    St Louis, Missouri

  • Sierra Eye Associates

    Reno, Nevada

  • Envision Ocular, LLC

    Bloomfield, New Jersey

  • Retina Vit Surgeons/Central NY

    Liverpool, New York

  • Duke Eye Center

    Durham, North Carolina

  • Graystone Eye

    Hickory, North Carolina

  • OSU Eye Physicians & Surgeons

    Columbus, Ohio

  • Mid Atlantic Retina - Wills Eye Hospital

    Philadelphia, Pennsylvania

  • Carolina Eyecare Physicians

    Mt. Pleasant, South Carolina

  • Charles Retina Institute

    Germantown, Tennessee

  • Southeastern Retina Associates

    Knoxville, Tennessee

  • Tennessee Retina PC.

    Nashville, Tennessee

  • Austin Research Center for Retina

    Austin, Texas

  • Austin Clinical Research LLC

    Austin, Texas

  • Retina Consultants of Texas

    Bellaire, Texas

  • Retina Consultants of Texas

    Houston, Texas

  • Retina Center of Texas

    Southlake, Texas

  • Piedmont Eye Center

    Lynchburg, Virginia

  • Spokane Eye Clinical Research

    Spokane, Washington

  • Emanuelli Research and Development Center LLC

    Arecibo, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.